BioNTech and Summit at #ESMO24 (Credit: Reynald Castañeda for Endpoints News)
September 16, 2024 11:41 AM EDTUpdated 04:10 PM
R&D

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Ayisha Sharma

News Reporter

Lei Lei Wu

News Reporter

BARCELONA — Last week, Sum­mit and Ake­so set the in­dus­try abuzz af­ter their bis­pe­cif­ic an­ti­body beat Mer­ck’s Keytru­da in a Phase 3 lung can­cer tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times